This Week in Nephrology — May 14, 2026

Welcome to This Week in Nephrology. This week we're covering 8 notable papers spanning new insights into disease pathophysiology, advances in diagnostics, and modernizing our therapeutic approaches. Let's dive in.

First, we'll look at a few papers that challenge our understanding of how kidney diseases develop and progress at a fundamental level, from the genetics of APOL1 to the mechanisms of GLP-1 receptor agonists.

A study in the Journal of the American Society of Nephrology investigated the mechanisms underlying APOL1 nephropathy, a condition for which 13% of African Americans carry a high-risk genotype [7]. The causes of kidney injury are not fully understood, but this work provides a major clue.

Methods Investigators used non-targeted metabolomics on glomeruli from transgenic mice and in cell lines expressing high-risk or low-risk APOL1 variants.

Results The key finding was that perturbed purine metabolism was the strongest metabolic differentiator between high- and low-risk APOL1 genotypes. Specifically, the high-risk G2 variant was found to downregulate the rate-limiting enzymes of purine biosynthesis, which led to ATP depletion and cytotoxicity in cells.

The Intervention Based on this finding, the researchers tested a potential therapy. They supplemented APOL1 G2-expressing cells and mice with AICAr, a precursor for purine biosynthesis. This intervention successfully rescued purine production, boosted ATP levels, reduced cytotoxicity in cells, and lowered albuminuria in the mouse model.

Clinical Implication This work provides a crucial mechanistic link between APOL1 risk variants and cell injury, identifying impaired purine metabolism as a central driver. It also points to a potential therapeutic strategy: boosting the purine biosynthesis pathway could be a way to mitigate APOL1-associated kidney disease.

Also on the theme of re-examining disease mechanisms, a mini-review in the American Journal of Kidney Diseases challenges a common assumption about GLP-1 receptor agonists [1]. While it's widely believed that the kidney benefits of these drugs are primarily driven by weight loss, this review presents an alternative hypothesis: that the kidney-protective effects are largely independent of weight loss. The authors present supportive data from human randomized trials, suggesting direct renal actions of these drugs. The clinical implication is that these agents may offer kidney protection even in patients who do not experience substantial weight loss, potentially broadening their utility. The authors call for more research to confirm this hypothesis.

Rounding out our look at fundamental biology, a paper in Nature provides a systems-level analysis of how organs build their own intrinsic nervous systems [3]. The study found a 'dual logic': a neural crest cell's lineage prefigures its spatial architecture, but local, organ-specific cues—particularly from the extracellular matrix—instruct its final molecular identity and function. For nephrologists, this deepens our understanding of the body-brain axis and the principles that underlie how our organs are wired, which is foundational to renal physiology and pathophysiology.

Next, we turn to how we diagnose and classify kidney diseases, with two papers aiming to bring more precision to our practice.

In the Journal of the American Society of Nephrology, investigators evaluated the clinical utility of donor-derived cell-free DNA for monitoring kidney transplant rejection [2].

The Study This observational cohort study analyzed over 900 plasma samples taken at the time of either an indication or a protocol kidney biopsy. The researchers compared a clinical prediction model, a model using donor-derived cell-free DNA alone, and a combined model to discriminate rejection.

Results Donor-derived cell-free DNA alone demonstrated strong predictive ability for rejection, with an area under the curve, or AUC, of 0.80 in the validation cohort. Combining it with clinical parameters improved the AUC even further to 0.87. Critically, the test had a major impact on risk stratification. For patients initially categorized as having an intermediate pre-test risk of rejection, adding the cell-free DNA result reclassified a large number. For instance, 72% of one intermediate-risk group were correctly reassigned to a low-risk category. The authors calculate that using these post-test probabilities could have safely avoided 482 biopsies in their cohort, with 91% of those being protocol biopsies. This study demonstrates that donor-derived cell-free DNA is a clinically impactful biomarker that can help reduce invasive procedures.

Moving from diagnostics to classification, a review in Kidney International proposes an updated framework for tubulointerstitial diseases, an area that has historically lacked the systematic classification seen in glomerular disease [6]. The author argues that as nephrology enters an era of personalized medicine, greater diagnostic precision for tubulointerstitial nephritis is essential. The proposed framework organizes these diseases into eight etiologic categories, including drug effect, autoimmune, infection-associated, and hereditary causes. The review also highlights recently described entities clinicians should be aware of, such as immune checkpoint inhibitor-associated TIN, IgG4-related TIN, and VEXAS syndrome. The key takeaway is a call for more structured thinking and classification in tubulointerstitial disease to improve diagnostics and patient outcomes.

And finally, we'll cover three papers that directly impact how we manage patients, from new guidelines in lupus nephritis to a critical safety warning for a common DMARD.

First, a timely review in Nephrology, Dialysis, Transplantation compares the newly released 2024 and 2025 guidelines for lupus nephritis from KDIGO, the American College of Rheumatology, and EULAR [8].

Key Themes Despite being developed by different groups, the guidelines show remarkable convergence. First, there is a major shift toward early combination regimens that include targeted therapies like belimumab, voclosporin, or obinutuzumab. Second is a strong emphasis on rapid glucocorticoid minimization. And third is the recognition that specific lupus nephritis therapy must be integrated into a broader chronic kidney disease management strategy, focusing on overall renoprotection. This convergence provides a clear, unified direction for managing this complex disease.

This theme of individualized therapy is echoed in a review on ANCA-associated vasculitis from Nature Reviews Nephrology [5]. The authors note that while current drugs can induce remission, we often struggle with over-treating some patients and under-treating others. The path forward lies in better biomarkers to guide therapy in real time. The review highlights promising candidates that require further validation, such as urinary levels of CD163 and CC-chemokine ligand 2. The ultimate goal is to better predict relapse and determine when it is safe to stop therapy, enabling true customization of treatment.

We end this week with a crucial and immediately practice-changing study from Seminars in Dialysis regarding the safety of low-dose methotrexate in patients receiving dialysis [4].

The Study Using linked healthcare databases in Ontario, Canada, investigators compared 55 new users of low-dose methotrexate to 407 new users of hydroxychloroquine. The primary outcome was the 90-day risk of death or hospitalization with myelosuppression, sepsis, pneumotoxicity, or hepatotoxicity.

Results The findings were alarming. The primary outcome occurred in about 29% of methotrexate users compared to just 7% of hydroxychloroquine users. After adjustment, this translated to a more than three-fold increase in risk. The adjusted absolute risk difference was 19.5%, meaning for every five dialysis patients started on methotrexate instead of hydroxychloroquine, one additional patient would be expected to die or be hospitalized with a serious adverse event within 90 days.

Conclusion The authors' conclusion is unequivocal: low-dose methotrexate should be avoided in dialysis patients whenever possible, and alternative DMARDs should be considered.

If you only have time for one paper this week, make it the study in Seminars in Dialysis on methotrexate use in dialysis patients [4]. The findings are stark: low-dose methotrexate was associated with a more than threefold increase in the risk of death or serious adverse events compared to hydroxychloroquine. This is a crucial safety signal that should lead clinicians to avoid this drug in the dialysis population whenever possible.

Here are the key takeaways from this week in Nephrology. First, avoid low-dose methotrexate in dialysis patients. A new study shows it's associated with a substantially increased risk of serious adverse events and death compared to hydroxychloroquine [4]. Second, in kidney transplant recipients, donor-derived cell-free DNA is a powerful tool. It improves rejection risk stratification and can help you safely avoid a significant number of protocol and indication biopsies [2]. Third, the new wave of lupus nephritis guidelines are aligned. They advocate for early combination therapy with targeted agents, rapid steroid tapering, and embedding treatment within a comprehensive CKD management strategy [8]. Fourth, emerging evidence suggests the kidney-protective benefits of GLP-1 receptor agonists may be largely independent of weight loss, pointing to direct renal mechanisms that could broaden their use [1]. And finally, basic science continues to uncover potential new therapeutic avenues, such as correcting impaired purine metabolism to mitigate kidney injury in patients with high-risk APOL1 genotypes [7].

That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.